Zota Health Care Ltd Q1 FY27 Earnings Analysis

- FY27 expansion planned to open 500-700 new stores, mostly COCO format (80%-90%). - Moderate store addition pace in Q2 and Q3 to focus on improving store-level profitability. - Same-store sales growth (SSG) remains strong at ~25%-30%, even without new stores. - New stores (~800 opened in FY26) are expected to deliver ~100% growth in their second year. - Continuing store additions in Q1, with ramp-up planned again in Q3 and Q4. - Confident of sustaining robust growth trajectory if execution on store additions and SSG continues. - Mature stores show healthy SSG of ~20%-24% annually. - Target to expand the Davaindia network to 5,000+ stores by FY29. - Revenue growth driven by scale benefits, integrated model, and private label portfolio.

- Zota Healthcare is confident about sustaining a robust growth trajectory driven by both store additions and same-store sales growth. - FY27 plans include opening 500-700 new stores, mostly COCO format, with moderated expansion pace in Q2 and Q3 to focus on improving store-level profitability. - Same-store sales growth remains strong at 25%-30%, even without new store additions, signaling substantial organic growth potential. - Newer stores (~800 opened in FY26) are expected to deliver close to 100% growth in their second year, further fueling revenue. - EBITDA turned positive in FY26 with margin improvement to 4.82%; operational leverage is expected to strengthen with scale. - Margins, especially gross margins in COCO stores, are sustainable and improving, supporting profitability expansion. - Overall, consistent margin expansion, strong sales growth, and operational efficiencies point toward significant improvement in earnings and profits moving forward, although the company does not provide explicit numerical guidance.

- The increase in inventory levels and capex amounting to around INR 114 crores for the year is primarily in anticipation of upcoming store openings. - The company plans to open between 500 to 700 new stores in FY27, with 80%-90% being COCO stores, necessitating capex for store setup. - Intangible Assets Under Development (approx. INR 14 crores) represent pre-operative expenses like drug licenses and regulatory approvals related to stores under development, indicating ongoing store expansion investments. - Marketing spend, which supports brand visibility and growth, has increased proportionally with sales but remains rational and controlled. - Overall, capex is focused on scaling store network and building a strong foundation for future growth and accessibility in affordable healthcare.

- There is no explicit mention of any current or future new fundraising through debt or equity in the transcript. - The company recently completed a significant QIP (Qualified Institutional Placement) of INR 350 crores, which strengthened their balance sheet and provided capital to support expansion. - No specific plans or guidance regarding raising new debt or equity were discussed or indicated during the call. - The focus remains on improving store-level profitability and moderate store expansion, supported by existing capital resources. - Overall, the discussion highlights confidence in growth without indicating immediate need for additional fundraising.

- As of the recent quarter, Zota Healthcare had around 400–600 stores under process (pipeline) for opening. - In the previous quarter, approximately 218 stores were launched. - Around 230–240 stores were already opened from the pipeline in the prior quarter. - For the current quarter, the company expects to open roughly 200+ additional stores from the remaining pipeline. - For the financial year FY27, Zota Healthcare plans to open between 500 to 700 stores overall. - Store additions will be moderated in the next 1-2 quarters with a focus on improving store-level profitability before ramping up again in Q3 and Q4. - Around 80% to 90% of these new stores will be COCO format, with 100–150 planned as FOFO stores.